This information is current as of July 8, 2017. A Novel Approach to the Analysis of Specificity, Clonality, and Frequency of HIV-Specific T Cell Responses Reveals a Potential Mechanism for Control of Viral Escape Daniel C. Douek, Michael R. Betts, Jason M. Brenchley, Brenna J. Hill, David R. Ambrozak, Ka-Leung Ngai, Nitin J. Karandikar, Joseph P. Casazza and Richard A. Koup References Subscription Permissions Email Alerts This article cites 32 articles, 24 of which you can access for free at: http://www.jimmunol.org/content/168/6/3099.full#ref-list-1 Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2002 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Downloaded from http://www.jimmunol.org/ by guest on July 8, 2017 J Immunol 2002; 168:3099-3104; ; doi: 10.4049/jimmunol.168.6.3099 http://www.jimmunol.org/content/168/6/3099 A Novel Approach to the Analysis of Specificity, Clonality, and Frequency of HIV-Specific T Cell Responses Reveals a Potential Mechanism for Control of Viral Escape1 Daniel C. Douek,2*† Michael R. Betts,* Jason M. Brenchley,* Brenna J. Hill,* David R. Ambrozak,* Ka-Leung Ngai,‡ Nitin J. Karandikar,§ Joseph P. Casazza,§ and Richard A. Koup* C ytotoxic T lymphocytes are unable to mediate full clearance, or adequate control of viral replication in HIV and SIV infections, in part because they select for escape mutations within viral epitopes (1–3). However, the cellular immune response may suppress the emergence of escape variants by targeting multiple epitopes, thereby reducing the probability of escape mutations at all epitopes occurring simultaneously in a single virus. Indeed, the most rapid emergence of escape from CD8⫹ T cells occurs during acute infection when fewer epitopes are targeted (1, 2, 4). After acute infection, a CD8⫹ T cell response is generated that is directed at multiple epitopes, and a broader response is associated with better control of viral replication and slower disease progression (2, 4, 5). Theoretically, the immune response may inhibit the emergence of escape by targeting individual epitopes with multiple TCR, thereby increasing the likelihood that sequence variants may be recognized. Recent studies have found that CD8⫹ T cells in HIV, SIV, EBV, and influenza often target a limited range of epitopes, and that the responses to individual epitopes are oligoclonal in composition (6 –13). For HIV, most studies have focused on single or small combinations of epitopes, with the assumption that they *Vaccine Research Center, National Institute of Allergy and Infectious Diseases, and † Department of Experimental Transplantation and Immunology, Medicine Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892; ‡MegaBases Inc., Northwestern University, Evanston Research Park, IL 60201; and §University of Texas Southwestern Medical Center, Dallas, TX 75390 Received for publication November 13, 2001. Accepted for publication January 8, 2002. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. 1 represent the total HIV-specific response (14). However, this assumption may lead to inappropriate conclusions about the overall breadth and clonality of the CD8⫹ T cell response (15, 16). Furthermore, the identification of TCR targeting HIV has generally relied on in vitro selection, cloning, and long-term propagation of cytolytic T cells (8, 17). However, the antiviral potential of CD8⫹ T cell clones is often, although not always, better associated with cytokine production than cytotoxic activity (18 –23). Therefore, previous studies were potentially biased toward cytotoxic clones with better in vitro growth characteristics, resulting in an incomplete picture of responding clonotypes. We used cytokine production to identify HIV-specific CD8⫹ T cells, and to carry out an unbiased analysis of the number of CD8⫹ T cell epitopes recognized and the number of TCR clonotypes that target immunodominant epitopes. We also examined the influence of sequence variation and antiretroviral therapy on the diversity and frequency of epitope-specific TCR clonotypes over time. Materials and Methods Cell stimulation and analysis Fifteen-mer peptides overlapping by 11 residues corresponding to sequences of HXBc2/Bal chimeric HIV strain (gag, pol, env, and nef) or HIV SF2 strain (tat, rev, vif, vpr, and vpu) were used. Responses were determined by intracellular cytokine staining (ICS)3 as previously described (24). For sorting of unfixed HIV-specific cells, peptide-matrix analysis was used to identify optimal gag 15-mer peptides (24). A total of 5 ⫻ 107 PBMC were stimulated with peptide and incubated at 37°C for 1 h at 107 cells/ml, then at 106/ml for 4 h. Cells were washed and incubated with IFN-␥ catch reagent (Miltenyi Biotech, Auburn, CA) according to the manufacturer’s instructions, and stained with fluorochrome-conjugated Abs to IFN-␥ (Miltenyi Biotech), CD69, and CD8. IFN-␥⫹CD69⫹CD8⫹ cells were sorted by FACS. All studies were approved by the institutions’ Institutional Review Board. This work was supported by AMFAR Grant no. 02680-28-RGV (to D.C.D.). 2 Address correspondence and reprint requests to Dr. Daniel C. Douek, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Room 3509, 40 Convent Drive, Bethesda, MD 20892. E-mail address: [email protected] Copyright © 2002 by The American Association of Immunologists 3 Abbreviations used in this paper: ICS, intracellular cytokine staining; qPCR, quantitative polymerase chain reaction; CDR3, third complementarity-determining region; TCRB, TCR -chain. 0022-1767/02/$02.00 Downloaded from http://www.jimmunol.org/ by guest on July 8, 2017 Escape from the CD8ⴙ T cell response through epitope mutations can lead to loss of immune control of HIV replication. Theoretically, escape from CD8ⴙ T cell recognition is less likely when multiple TCRs target individual MHC/peptide complexes, thereby increasing the chance that amino acid changes in the epitope could be tolerated. We studied the CD8ⴙ T cell response to six immunodominant epitopes in five HIV-infected subjects using a novel approach combining peptide stimulation, cell surface cytokine capture, flow cytometric sorting, anchored RT-PCR, and real-time quantitative clonotypic TCR tracking. We found marked variability in the number of clonotypes targeting individual epitopes. One subject recognized a single epitope with six clonotypes, most of which were able to recognize and lyse cells expressing a major epitope variant that arose. Additionally, multiple clonotypes remained expanded during the course of infection, irrespective of epitope variant frequency. Thus, CD8ⴙ T cells comprising multiple TCR clonotypes may expand in vivo in response to individual epitopes, and may increase the ability of the response to recognize virus escape mutants. The Journal of Immunology, 2002, 168: 3099 –3104. CLONOTYPIC ANALYSIS OF HIV-SPECIFIC CD8⫹ T CELLS 3100 Identification of TCR -chain (TCRB) sequences and quantitative clonotypic PCR Sorted peptide-specific cells (5000 from each stimulation) were lysed and mRNA extracted (Oligotex kit, Qiagen, Valencia, CA). Anchored RT-PCR was performed using a modified version of the SMART (switching mechanism at 5⬘ end of RNA transcript) procedure (25) and a TCRB constant region 3⬘ primer for the PCR, to obtain TCRB PCR products from the 5⬘ end to the start of the TCRB constant region. The PCR product was ligated into the pGEMT Easy vector (Promega, Madison, WI) and used to transform Escherichia coli. Colonies were selected, amplified by PCR with M13 primers, and sequenced. PBMC were lysed in proteinase K (Boehringer Mannheim, Indianapolis, IN), and real-time quantitative PCR (qPCR) was performed on 5 l cell lysate (equivalent to 50,000 cells) with clonotypespecific primers and probes. Probes were labeled with FAM (6⬘ carboxyflourescene) and QSY7 quencher (MegaBases, Chicago, IL). A standard curve was plotted for each clonotype and template copies were calculated. Plasmid template for the standards was that used in the sequencing of each third complementarity-determining region (CDR3). Samples were analyzed in duplicate. Full details of all primers, components, and cycling temperatures are available upon request. Chromium release assay Results Breadth and specificity of total HIV-specific CD8⫹ T cell responses Seven HIV-infected individuals were assessed for their total CD8⫹ T cell responses to HIV by ICS for IFN-␥ using overlapping 15mer peptide pools covering the entire HIV sequence, thus avoiding bias to previously identified epitopes. Their virologic and clinical characteristics around the time of the study are summarized in Table I. Subjects TX4 –7 were noncompliant to therapy. Although most subjects mounted their largest response to gag, there were marked differences in the breadth and magnitude of their responses, irrespective of clinical status (Fig. 1A). We examined their responses to the 122 individual overlapping peptides covering HIV gag (to which all subjects mounted a response). Subjects TX4, 6, and 7 responded to a restricted set of gag epitopes, whereas subjects TX1, 2, 3, and 5 mounted broader responses (Fig. 1B). Subject TX7 was notable in that the total CD8⫹ T cell response to HIV was almost completely directed against one gag epitope. Identification of CD8⫹ T cell clones specific for immunodominant HIV epitopes To determine the clonotypic diversity of HIV-specific responses, we sorted by flow cytometry CD8⫹ T cells responding to six HIV Table I. Clinical details of subjects at time of analysis Subject Age Infection (years) Current Therapy Viral Load (copies/ml) CD4 Count (cells/l) TX1 TX2 TX3 TX4 27 43 48 46 17 5 6 1.5 ⬍50 4814 7846 ⬍400 862 794 642 274 TX5 TX6 TX7 29 65 30 1 5 3 None None None d4T, 3TC, Efaverenz d4T, 3TC Combivir Combivir 97662 36577 ⬍400 471 462 627 FIGURE 1. Responses to HIV peptides in HIV-infected subjects by ICS. A, CD8⫹ T cell to peptide pools are expressed as the percentage of IFN-␥⫹CD8⫹ T cells. B, CD8⫹ T cell responses to 122 individual peptides covering gag. Each peak represents the response to an individual peptide. epitopes, which elicited the highest frequency responses, in five subjects: TX1, 2, 3, 6, and 7 (indicated with an asterisk in Fig. 1). Identification of cells by ICS requires permeabilization, rendering RNA unamenable to analysis. Therefore, we used cell surface Abmediated capture of secreted IFN-␥, and CD69 induction. The TCRB CDR3 of the sorted T cells were amplified by anchored RT-PCR to ensure that all HIV-specific TCRB sequences were amplified without bias to particular TCRBV families. Thus, all epitope-specific clonotypes were represented in the PCR product with a relative frequency reflecting that in the original sorted cell population. Table II shows the sequences and frequencies of the TCRB CDR3 that define the clonotypes responding to dominant gag epitopes in each subject. There was heterogeneity in the number of T cell clonotypes elicited to the epitopes. Three of six epitopes elicited monoclonal responses, whereas the others elicited oligo- or polyclonal responses. Such heterogeneity occurred within the response of TX2 to two gag epitopes (Fig. 1); one epitope elicited a response consisting of 15 clonotypes, while the other was monoclonal. We confirmed the frequency and TCRBV subfamily of their epitope-specific clones by flow cytometry with TCR chain-specific mAbs (data not shown). These results show that multiple T cell clonotypes can target individual epitopes during HIV infection. Furthermore, there is considerable CDR3 sequence and length diversity among clonotypes targeting a single epitope in a subject. In addition, there was no bias to particular TCRBV families in any of Downloaded from http://www.jimmunol.org/ by guest on July 8, 2017 PBMC were cultured with peptide-loaded autologous EBV-transformed B cells, restimulated on day 7, and incubated for a further week. 51Cr-release assay was performed on day 14, with 51Cr-labeled autologous EBV-transformed B cell targets loaded with SLYNTVATL (SL9) or SLYNTIAVL (1 g/ml). 51Cr release was detected, and specific lysis was determined as: ((experimental release ⫺ spontaneous release)/(total release ⫺ spontaneous release)) ⫻ 100. The Journal of Immunology 3101 Table II. CDR3 sequences of HIV gag epitope-specific CD8⫹ T cells from five subjects, their frequency out of 100 bacterial clones, and their length with respect to the full genomic sequencea Subject TX1 TX2 Epitope 1 TX7 a CDR3 Amino Acid Sequence (VDJ regions) TCRBJ Locus % Frequency CDR3 Length 2.1 8.2 8.2 14.1 14.1 3.1 3.1 3.1 22.1 22.1 5 18.1 18.1 2.1 7.1/3 24.1 2.1 FYICS------ARDDGP---SYEQYFGPGTRLTVTE SAVYFCASS--TGTAM----NTEAFFGQGTRLTVVE SAVYFCASS--QGSYGFK------YFGPGTRLTVTE SLYFCASS---LDGQGTT----EQYFGPGTRLTVTE SLYFCASS---TTGMTS----QPQHFGDGTRLSILE SMYLCASS---LGLH------YEQYFGPGTRLTVTE SMYLCASS---DGTGVIG----GYTFGSGTRLTVVE SMYLCASS---RVGN------NEQFFGPGTRLTVLE SAMYFCASS--RAAPYD-----EQFFGPGTRLTVLE SAMYFCASS--IGLAGF----NEQFFGPGTRLTVLE SALYLCASS--FGRGP----YNEQFFGPGTRLTVLE SAAYFCASS--PLTLGTGS-TGELFFGEGSRLTVLE SAAYFCASS--IATGT----QETQYFGPGTRLLVLE FYICS------APGTGN----YEQYFGPGTRLTVTE SALYLCASS--QKGLL-----GELFFGEGSRLTVLE DAAMYLCATS-RDLTGSV----GYTFGSGTRLTVVE FYICS------DGP------SYEQYFGPGTRLTVTE 2.7 1.1 2.7 2.7 1.5 2.7 1.2 2.1 2.1 2.1 2.1 2.2 2.5 2.7 2.2 1.2 2.7 100 25 7 16 3 6 6 3 4 4 7 6 4 3 3 3 100 2 1 –1 1 0 –1 1 –2 –1 0 0 3 1 1 –1 1 –1 25.1 2.1a 2.1b 7.1/2/3 5.1a 5.1b 8.1 6.4 7.1 17 SAVYFCASS--HNEL----TNEKLFFGSGTQLSVLE FYICS------DSL------TGELFFGEGSRLTVLE FYICS------DEGGRT---YNEQFFGPGTRLTVLE SALYLCASS--QDVG-----TDTQYFGPGTRLTVLE SALYLCASS--FDRDK--------FFGPGTRLTVLE SALYLCASS--FDPP-----NTEAFFGQGTRLTVVE SAVYFCAS---RYTG-------EQYFGPGTRLTVTE SAMYLCASR--ITGG------NEQFFGPGTRLTVLE SALYLCASS--QERTMLD----IQYFDAGTRLSVLE TAFYLCASSI-TG-------NTEAFFGQGTRLTVVE 1.4 2.2 2.1 2.3 2.1 1.1 2.7 2.1 2.4 1.1 100 40 38 22 11 77 3 3 4 2 0 –2 1 –1 –4 0 –2 –2 0 –2 Peptides used for stimulation are marked with an asterisk in Fig. 1. these responses, and no clear correlation between disease state and the number of clonotypes elicited by the epitopes. Longitudinal analysis of epitope sequence variability To assess whether multiple CD8⫹ T cell clonotypes specific for a particular HIV epitope influence the ability of epitope variants to escape a CD8⫹ T cell response, we studied subject TX7 who recognized only one epitope in gag (SL9) during a 3-year period. This epitope has been shown to resist escape from CD8⫹ T cells, partially because CD8⫹ T cells can recognize multiple variants of this epitope (26, 27). Six different TCR clonotypes targeted this epitope in subject TX7. Therefore, we could address whether epitope variants arose and dominated the viral quasispecies, whether the multiple TCR clonotypes could recognize these variants, and whether multiple clonotypes remained expanded in vivo over time. TX7 was initially treated with antiretroviral therapy and his viral load was suppressed; however, he subsequently became noncompliant, and his viral load rebounded. Plasma and PBMC virus were sequenced at the SL9 epitope region at multiple time points before and after therapy began. Initially, the SL9 sequence SLYNTVATL was present in all viruses sequenced. Then during therapy, three variants emerged, SLYNTVAVL, SLYNTIATL, and SLYNTIAVL, the latter being predominant. None of the amino acid changes were at MHC anchor residues, and all four peptides can bind to HLA-A2, but have markedly variable recognition by different T cell clones (27). Later, the original sequence reemerged and persisted. This could simply be a result of the loss of selective advantage of the variants due to intermittent compliance with therapy (28). However, these particular variant epitopes have been shown to arise in the absence of therapy (27), and thus, they may have failed to escape recognition by the CD8⫹ T cell response. Quantitative clonotype PCR of epitope-specific CD8⫹ T cells To determine whether the different CD8⫹ T cell clonotypes showed differential recognition of the variant epitope sequences, we stimulated PBMC from TX7 at 156 wk after therapy initiation with either the original SL9 or the predominant variant epitope, SLYNTIAVL. The frequencies of responding CD8⫹ T cells were 2.8 and 2.6%, respectively, suggesting that both peptides stimulated a CD8⫹ T cell response, and that neither epitope escaped immune recognition. We sorted cells responding to each peptide and probed for the presence of the clonotypes by qPCR. We designed CDR3-specific primers and probes for each of the six T cell clonotypes identified in subject TX7. The sensitivity of this assay was one clonotype cell in 100,000 PBMC (data not shown). The specificity of qPCR for HIV-specific clonotypes of TX7 was confirmed as follows: 1) no amplification of clonotype sequences was seen in PBMC from five uninfected adults; 2) no amplification was seen in the PBMC of TX7 when probed for the two predominant HIV-specific clonotypes of TX6; and 3) no HIV-specific clonotypes were detected in sorted CMV-specific CD8⫹ T cells from TX7 (Fig. 2A). As expected, SL9-specific CD8⫹ T cells contained all clonotypes (except clone BV6.4, which was no longer detectable by qPCR at this time point, as discussed in the next section). SLYN TIAVL-specific T cells contained the same clonotypes at the same relative frequencies as SL9-specific T cells, except that clone BV17 was undetectable (Fig. 2B). Thus, the TCR expressed by BV17 only recognized SL9, whereas the TCR expressed by the four other clones were more promiscuous and could respond to both SL9 and the variant epitopes. To confirm that this promiscuity was not due to the high peptide concentration used in the assay, we stimulated with suboptimal peptide concentrations. We found that Downloaded from http://www.jimmunol.org/ by guest on July 8, 2017 TX2 Epitope 2 TX3 TX6 TCRBV Locus 3102 CLONOTYPIC ANALYSIS OF HIV-SPECIFIC CD8⫹ T CELLS magnitude of the CD8⫹ T cell response to SL9 correlated positively with fluctuations in viral load resulting from nonadherence to therapy, and multiple T cell clonotypes were present at each time point analyzed, although their relative frequencies changed over the 3-year study period. Clone BV6, while initially well represented, steadily decreased in frequency and was undetectable after 96 wk. Notably, clone BV17, which recognized SL9 but not the variant SLYNTIAVL epitope (Fig. 2A) became undetectable 20 wk after therapy initiation, when SLYNTIAVL was transiently predominant, yet subsequently expanded to become the second most frequent clonotype. Thus, the absolute and relative frequencies of the clonotypes changed not only in relation to viral load, but also with respect to each other and to viral epitope variation. Discussion the responses to both epitopes declined, and that the response to the variant peptide was also apparent at lower peptide concentrations (Fig. 2C). Furthermore, short-term lines stimulated with either SL9 or SLYNTIAVL lysed autologous B cells pulsed with either peptide (Fig. 2D), indicating that at least a proportion of the cells mediated cytotoxicity. Longitudinal analysis of clonotype frequency To assess changes in the frequencies of the SL9-specific clonotypes with respect to viral load and epitope sequence, we performed clonotypic qPCR on longitudinal samples of the PBMC of TX7. Fig. 3 shows the changes in viral load, epitope sequence, epitope-specific CD8⫹ T cell frequency by ICS (lower panel), and epitope-specific clonotype frequency by qPCR (upper panel). The Downloaded from http://www.jimmunol.org/ by guest on July 8, 2017 FIGURE 2. Responses to original and variant epitopes. A, PBMC from TX7 (96 wk after therapy initiation) and from five healthy donors (nos. 1–5) were probed by qPCR for the six HIV-specific TX7 clones (Table I). CMV-specific CD8⫹ T cells from TX7 were also probed. PBMC from subjects TX6 and TX7 were probed for two of TX6’s HIV-specific clones. B, Relative frequencies, by qPCR, of five TX7 clones in sorted CD8⫹ T cells specific for SLYNTVATL (filled bars) and SLYNTIAVL (open bars). C, TX7 PBMC stimulated with different concentrations of SLYNTVATL (F) or SLYNTIAVL (E). The frequency of responding cells by ICS is expressed as the percentage of IFN-␥⫹CD8⫹ T cells. D, Percentage of specific lysis of SLYNTVATL- (f) or SLYNTIAVL-pulsed (Œ), or unpulsed (⽧) autologous B cells by SLYNTVATL-specific (left) and SLYNTIAVL-specific (right) T cell lines from TX7. In this study we identified, characterized, and quantified HIV-specific CD8⫹ T cell clones in an unbiased manner using a novel approach that combines in vitro peptide stimulation, cell surface cytokine capture, flow cytometric sorting, anchored TCRB locus RT-PCR, and clonotypic qPCR. This approach obviated skewing of the clonotype population by prolonged stimulation and propagation. Furthermore, we used an anchored RT-PCR step to amplify all TCRB CDR3 of all T cell clones present in the sorted population, without the incomplete coverage of, and bias to, particular TCRBV families conferred by TCRBV-specific PCR primers. This approach requires no prior knowledge of either the specific epitope or the MHC restricting element, and when combined with qPCR, it allows for sensitive and specific quantification of clonotypes at any point, before or after the time at which clonotypes were originally identified. It should be noted that recent papers have demonstrated heterogeneity in cytokine production by HIV-specific T cells and that not all secrete IFN-␥ (20 –23). Therefore, we may be underestimating the frequency of responding T cells. However, although not absolutely complete, this type of approach offers a broader analysis than more limited studies performed in the past with limited sets of peptides or Ags. We found marked heterogeneity in the epitope breadth and magnitude of HIV-specific CD8⫹ T cell responses, with no apparent relation to disease state, which could arise as a result of attempts by the immune system to control multiple epitope variants (1–3). Escape of an individual epitope would be more difficult in the presence of multiple specific T cell clonotypes, which could arise de novo and may act to limit virus escape (27, 29, 30), or may arise as a result of recruitment of new clonotypes in response to epitope variants (31, 32). Thus, we observed marked heterogeneity in the clonality of T cells responding to immunodominant HIV gag epitopes. Indeed, one epitope was targeted by 15 TCR clonotypes, indicating that multiple TCR may expand in vivo in response to a single HIV epitope. The diversity of clonotypes specific for an HIV epitope could influence the appearance and effects of viral escape mutations. In subject TX7, whose CD8⫹ T cell response to HIV consisted almost entirely of six clonotypes directed against one gag epitope, there was transient expression of two nonsynonymous mutations in that epitope during antiretroviral therapy. Although these mutations can affect T cell recognition (26, 27), this polyclonal response persisted. Furthermore, even though one clonotype did not respond to the mutated epitope, the viral variants failed to escape the CD8⫹ T cell response of the four remaining clonotypes, which were able to recognize, produce cytokine in response to, and lyse target cells expressing the mutated epitope. It should be noted that our analysis The Journal of Immunology 3103 of recognition of the variant epitope depended on the use of peptide-pulsed targets. To rule out aberrant processing and presentation of the variant epitopes, one would ideally perform this analysis using the Ags encoded in minigenes, or vaccinia virus vectors. Although the viral variants that emerged failed to persist as dominant species, genuine viral escape mutants may not always reach fixation because the selective advantage of the variant might be lost (28). This is especially the case in a subject such as TX7, who was intermittently compliant with therapy. However, these particular variant epitopes have been observed in the absence of therapy and so may represent escape from immunologic pressure (27). Although the epitope variants described in this subject are genuine escape mutants, the ultimate effect of mounting a broad CTL response which can recognize those epitopes is to abrogate the immunologic and virologic consequences of such escape. Thus, while a multiclonal CTL response would not affect the probability of viral escape (indeed, it might increase), it does increase the probability of recognition of these escape mutants. It is of note that when viral load and HIV-specific CD8⫹ T cell frequencies were high, the frequency of clonotypes detected by qPCR was higher than that of responding T cells detected by ICS (Fig. 3). Yet when virus was suppressed, the frequencies were equal and the ratio was one. During any time interval, it is likely that only a fraction of all epitope-specific CD8⫹ T cells will produce an optimal intracellular response, even when exposed to optimal levels of Ag and costimulation (33). Thus, while ICS may only detect those CD8⫹ T cells which can respond under the specific conditions of the assay, qPCR may detect all clonotype cells, irrespective of whether they are in a state of responsiveness to peptide stimulation. Our findings indicate that an understanding of HIV epitope escape from CD8⫹ T cells must take into account the plasticity of the response against particular epitopes. Recognition of one or multiple epitopes, use of multiple TCR clonotypes, and HLA associations may all play roles in controlling HIV replication. Furthermore, in subjects immunized with HIV vaccines, it is possible that the infecting virus would rapidly mutate away from the epitope sequences used to elicit immunity. Our data suggest that strategies which elicit multiple T cell clonotypes against HIV epitopes may potentially provide immunity that can tolerate such mutations. References 1. Allen, T. M., D. H. O’Connor, P. Jing, J. L. Dzuris, B. R. Mothe, T. U. Vogel, E. Dunphy, M. E. Liebl, C. Emerson, N. Wilson, et al. 2000. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 407:386. 2. Price, D. A., P. J. Goulder, P. Klenerman, A. K. Sewell, P. J. Easterbrook, M. Troop, C. R. Bangham, and R. E. Phillips. 1997. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc. Natl. Acad. Sci. USA 94:1890. 3. Wolinsky, S. M., B. T. M. Korber, A. U. Neumann, M. Daniels, K. J. Kunstman, A. J. Whetsell, M. R. Furtado, Y. Cao, D. D. Ho, J. T. Safrit, and R. A. Koup. 1996. Adaptive evolution of human immunodeficiency virus type 1 during the natural course of infection. Science 272:537. 4. Altfeld, M., E. S. Rosenberg, R. Shankarappa, J. S. Mukherjee, F. M. Hecht, R. L. Eldridge, M. M. Addo, S. H. Poon, M. N. Phillips, G. K. Robbins, et al. 2001. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J. Exp. Med. 193:169. 5. Harrer, T., E. Harrer, S. A. Kalams, P. Barbosa, A. Trocha, R. P. Johnson, T. Elbeik, M. B. Feinberg, S. P. Buchbinder, and B. D. Walker. 1996. Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection: breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load. J. Immunol. 156:2616. 6. Moss, P. A., R. J. Moots, W. M. Rosenberg, S. J. Rowland-Jones, H. C. Bodmer, A. J. McMichael, and J. I. Bell. 1991. Extensive conservation of ␣ and  chains of the human T-cell antigen receptor recognizing HLA-A2 and influenza A matrix peptide. Proc. Natl. Acad. Sci. USA 88:8987. 7. Pantaleo, G., J. F. Demarest, H. Soudeyns, C. Graziosi, F. Denis, J. W. Adelsberger, P. Borrow, M. S. Saag, G. M. Shaw, R. P. Sekaly, and A. S. Fauci. 1994. Major expansion of CD8⫹ T lymphocytes with a predominant V usage during the primary immune response to HIV. Nature 370:463. 8. Kalams, S. A., R. P. Johnson, A. K. Trocha, M. J. Dynan, S. Ngo, R. T. D’Aquila, J. T. Kurnick, and B. D. Walker. 1994. Longitudinal analysis of T cell receptor (TCR) gene usage by human immunodeficiency virus 1 envelope-specific cytotoxic T lymphocyte clones reveals a limited TCR repertoire. J. Exp. Med. 179: 1261. 9. Kalams, S. A., R. P. Johnson, M. J. Dynan, K. E. Hartman, T. Harrer, E. Harrer, A. K. Trocha, W. A. Blattner, S. P. Buchbinder, and B. D. Walker. 1996. T cell receptor usage and fine specificity of human immunodeficiency virus 1-specific cytotoxic T lymphocyte clones: analysis of quasispecies recognition reveals a dominant response directed against a minor in vivo variant. J. Exp. Med. 183: 1669. Downloaded from http://www.jimmunol.org/ by guest on July 8, 2017 FIGURE 3. Clonotype frequency in HIV infection. The frequency of six SLYNT VATL-specific clones of TX7 was measured in PBMC ⬎3 years by qPCR. The frequency of each clone as a percentage of PBMC is represented by a different colored bar (top). The arrow shows when HIV-specific clones were identified. Middle, Plasma and PBMC virus sequence. Blue boxes denote SLYNTVATL, red boxes denote SLYNTIAVL, hatched box denotes the variant mix. Up to 20 sequences were analyzed at each time point. Lower, Frequency of SLYNTVATL-specific IFN-␥⫹CD8⫹ T cells in TX7 PBMC (filled bars) determined by ICS, and viral load (red circles). 3104 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. CD8⫹ T cells produce antiviral cytokines but are impaired in cytolytic function. J. Exp. Med. 192:63. Kostense, S., G. S. Ogg, E. H. Manting, G. Gillespie, J. Joling, K. Vandenberghe, E. Z. Veenhof, D. van Baarle, S. Jurriaans, M. R. Klein, and F. Miedema. 2001. High viral burden in the presence of major HIV-specific CD8⫹ T cell expansions: evidence for impaired CTL effector function. Eur. J. Immunol. 31:677. Betts, M. R., D. A. Ambrozak, D. C. Douek, S. E. Bonhoeffer, J. M. Brenchley, J. P. Casazza, R. A. Koup, and L. J. Picker. 2001. Analysis of total human immunodeficiency virus (HIV)-specific CD4 and CD8 T-cell responses: relationship to viral load in untreated HIV infection. J. Virol. 75:11983. Chenchik, A., Y. Zhu, L. Diatchenko, R. Li, J. Hill, and P. Siebert. 1998. Generation and use of high quality cDNA from small amounts of total RNA by SMART PCR. In RT-PCR Methods for Gene Cloning and Analysis. P. Siebert and J. Larrick, eds. BioTechniques Books, Natick, p. 305. Sewell, A. K., G. C. Harcourt, P. J. Goulder, D. A. Price, and R. E. Phillips. 1997. Antagonism of cytotoxic T lymphocyte-mediated lysis by natural HIV-1 altered peptide ligands requires simultaneous presentation of agonist and antagonist peptides. Eur. J. Immunol. 27:2323. Brander, C., K. E. Hartman, A. K. Trocha, N. G. Jones, R. P. Johnson, B. Korber, P. Wentworth, S. P. Buchbinder, S. Wolinsky, B. D. Walker, and S. A. Kalams. 1998. Lack of strong immune selection pressure by the immunodominant, HLAA*0201-restricted cytotoxic T lymphocyte response in chronic human immunodeficiency virus-1 infection. J. Clin. Invest. 101:2559. Kelleher, A. D., C. Long, E. C. Holmes, R. L. Allen, J. Wilson, C. Conlon, C. Workman, S. Shaunak, K. Olson, P. Goulder, et al. 2001. Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. J. Exp. Med. 193:375. Haas, G., U. Plikat, P. Debre, M. Lucchiari, C. Katlama, Y. Dudoit, O. Bonduelle, M. Bauer, H. G. Ihlenfeldt, G. Jung, and M. B. Meyer. 1996. Dynamics of viral variants in HIV-1 Nef and specific cytotoxic T lymphocytes in vivo. J. Immunol. 157:4212. Weidt, G., W. Deppert, O. Utermohlen, J. Heukeshoven, and F. Lehmann-Grube. 1995. Emergence of virus escape mutants after immunization with epitope vaccine. J. Virol. 69:7147. Goulder, P. J., A. K. Sewell, D. G. Lalloo, D. A. Price, J. A. Whelan, J. Evans, G. P. Taylor, G. Luzzi, P. Giangrande, R. E. Phillips, and A. J. McMichael. 1997. Patterns of immunodominance in HIV-1-specific cytotoxic T lymphocyte responses in two human histocompatibility leukocyte antigens (HLA)-identical siblings with HLA-A*0201 are influenced by epitope mutation. J. Exp. Med. 185: 1423. Nowak, M. A., R. M. May, R. E. Phillips, S. Rowland-Jones, D. G. Lalloo, S. McAdam, P. Klenerman, B. Koppe, K. Sigmund, C. R. Bangham, et al. 1995. Antigenic oscillations and shifting immunodominance in HIV-1 infections. Nature 375:606. Germain, R. N. 2001. The art of the probable: system control in the adaptive immune system. Science 293:240. Downloaded from http://www.jimmunol.org/ by guest on July 8, 2017 10. Callan, M. F., N. Steven, P. Krausa, J. D. Wilson, P. A. Moss, G. M. Gillespie, J. I. Bell, A. B. Rickinson, and A. J. McMichael. 1996. Large clonal expansions of CD8⫹ T cells in acute infectious mononucleosis. Nat. Med. 2:906. 11. Sourdive, D. J., K. Murali-Krishna, J. D. Altman, A. J. Zajac, J. K. Whitmire, C. Pannetier, P. Kourilsky, B. Evavold, A. Sette, and R. Ahmed. 1998. Conserved T cell receptor repertoire in primary and memory CD8 T cell responses to an acute viral infection. J. Exp. Med. 188:71. 12. Wilson, J. D., G. S. Ogg, R. L. Allen, P. J. Goulder, A. Kelleher, A. K. Sewell, C. A. O’Callaghan, S. L. Rowland-Jones, M. F. Callan, and A. J. McMichael. 1998. Oligoclonal expansions of CD8⫹ T cells in chronic HIV infection are antigen specific. J. Exp. Med. 188:785. 13. Chen, Z. W., Y. Li, X. Zeng, M. J. Kuroda, J. E. Schmitz, Y. Shen, X. Lai, L. Shen, and N. L. Letvin. 2001. The TCR repertoire of an immunodominant CD8⫹ T lymphocyte population. J. Immunol. 166:4525. 14. Ogg, G. S., X. Jin, S. Bonhoeffer, P. R. Dunbar, M. A. Nowak, S. Monard, J. P. Segal, Y. Cao, S. L. Rowland-Jones, V. Cerundolo, et al. 1998. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 279:2103. 15. Dalod, M., M. Dupuis, J. C. Deschemin, D. Sicard, D. Salmon, J. F. Delfraissy, A. Venet, M. Sinet, and J. G. Guillet. 1999. Broad, intense anti-human immunodeficiency virus (HIV) ex vivo CD8⫹ responses in HIV type 1-infected patients: comparison with anti-Epstein-Barr virus responses and changes during antiretroviral therapy. J. Virol. 73:7108. 16. Betts, M. R., J. P. Casazza, B. A. Patterson, S. Waldrop, W. Trigona, T. M. Fu, F. Kern, L. J. Picker, and R. A. Koup. 2000. Putative immunodominant human immunodeficiency virus-specific CD8⫹ T-cell responses cannot be predicted by major histocompatibility complex class I haplotype. J. Virol. 74:9144. 17. Walker, B. D., C. Flexner, K. Birch-Limberger, L. Fisher, T. J. Paradis, A. Aldovini, R. Young, B. Moss, and R. T. Schooley. 1989. Long-term culture and fine specificty of human cytotoxic T lymphocyte clones reactive with human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 86:9514. 18. Martz, E., and D. M. Howell. 1989. CTL: virus control cells first and cytolytic cells second? DNA fragmentation, apoptosis and the prelytic halt hypothesis. Immunol. Today 10:79. 19. Guidotti, L. G., R. Rochford, J. Chung, M. Shapiro, R. Purcell, and F. V. Chisari. 1999. Viral clearance without destruction of infected cells during acute HBV infection. Science 284:825. 20. Sandberg, J. K., N. M. Fast, and D. F. Nixon. 2001. Functional heterogeneity of cytokines and cytolytic effector molecules in human CD8⫹ T lymphocytes. J. Immunol. 167:181. 21. Goulder, P. J., Y. Tang, C. Brander, M. R. Betts, M. Altfeld, K. Annamalai, A. Trocha, S. He, E. S. Rosenberg, G. Ogg, et al. 2000. Functionally inert HIVspecific cytotoxic T lymphocytes do not play a major role in chronically infected adults and children. J. Exp. Med. 192:1819. 22. Appay, V., D. F. Nixon, S. M. Donahoe, G. M. Gillespie, T. Dong, A. King, G. S. Ogg, H. M. Spiegel, C. Conlon, C. A. Spina, et al. 2000. HIV-specific CLONOTYPIC ANALYSIS OF HIV-SPECIFIC CD8⫹ T CELLS